On Oct. 16, President Trump announced a plan to reduce the price of brand-name GLP-1 drugs, such as Ozempic and Wegovy, to $150 a month. This declaration, despite ongoing negotiations between drugmakers and the administration, led to a notable decline in stock prices for Novo Nordisk and Eli Lilly. For many patients struggling with high costs, this figure appeared to offer a glimmer of hope.
However, the response from industry insiders reveals a deeper skepticism. Colleagues reached out with questions about the implications of this price cut on research suppliers and pharmacy practices. The excitement among patients may not translate into sustainable changes in the pharmaceutical landscape, as the complexities of drug pricing and market dynamics remain unresolved. The potential for disruption in sourcing and regulatory practices could challenge the stability of the GLP-1 market, raising concerns about accessibility and long-term viability.
Use the database as your supply chain compass →
